Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PLCB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PLCB1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PLCB1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PLCB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLCB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PLCB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PLCB1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PLCB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLCB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00459956 | Endometrium | AEH | regulation of embryonic development | 18/2100 | 64/18723 | 1.65e-04 | 2.15e-03 | 18 |
GO:00308564 | Endometrium | AEH | regulation of epithelial cell differentiation | 33/2100 | 154/18723 | 1.81e-04 | 2.32e-03 | 33 |
GO:000206415 | Endometrium | AEH | epithelial cell development | 43/2100 | 220/18723 | 1.94e-04 | 2.48e-03 | 43 |
GO:00509008 | Endometrium | AEH | leukocyte migration | 64/2100 | 369/18723 | 2.57e-04 | 3.04e-03 | 64 |
GO:00457877 | Endometrium | AEH | positive regulation of cell cycle | 56/2100 | 313/18723 | 2.73e-04 | 3.14e-03 | 56 |
GO:00486387 | Endometrium | AEH | regulation of developmental growth | 58/2100 | 330/18723 | 3.45e-04 | 3.80e-03 | 58 |
GO:00480092 | Endometrium | AEH | insulin-like growth factor receptor signaling pathway | 12/2100 | 37/18723 | 4.83e-04 | 4.97e-03 | 12 |
GO:00026858 | Endometrium | AEH | regulation of leukocyte migration | 39/2100 | 210/18723 | 1.06e-03 | 9.33e-03 | 39 |
GO:00610289 | Endometrium | AEH | establishment of endothelial barrier | 13/2100 | 46/18723 | 1.23e-03 | 1.06e-02 | 13 |
GO:00486396 | Endometrium | AEH | positive regulation of developmental growth | 33/2100 | 174/18723 | 1.72e-03 | 1.38e-02 | 33 |
GO:00026838 | Endometrium | AEH | negative regulation of immune system process | 69/2100 | 434/18723 | 1.76e-03 | 1.41e-02 | 69 |
GO:00447726 | Endometrium | AEH | mitotic cell cycle phase transition | 67/2100 | 424/18723 | 2.37e-03 | 1.78e-02 | 67 |
GO:00975299 | Endometrium | AEH | myeloid leukocyte migration | 39/2100 | 220/18723 | 2.55e-03 | 1.88e-02 | 39 |
GO:00454467 | Endometrium | AEH | endothelial cell differentiation | 24/2100 | 118/18723 | 2.71e-03 | 1.96e-02 | 24 |
GO:00900686 | Endometrium | AEH | positive regulation of cell cycle process | 41/2100 | 236/18723 | 2.94e-03 | 2.09e-02 | 41 |
GO:00328743 | Endometrium | AEH | positive regulation of stress-activated MAPK cascade | 25/2100 | 126/18723 | 3.18e-03 | 2.24e-02 | 25 |
GO:00459278 | Endometrium | AEH | positive regulation of growth | 44/2100 | 259/18723 | 3.28e-03 | 2.30e-02 | 44 |
GO:00703044 | Endometrium | AEH | positive regulation of stress-activated protein kinase signaling cascade | 25/2100 | 128/18723 | 3.95e-03 | 2.65e-02 | 25 |
GO:00018198 | Endometrium | AEH | positive regulation of cytokine production | 71/2100 | 467/18723 | 4.76e-03 | 3.02e-02 | 71 |
GO:00072546 | Endometrium | AEH | JNK cascade | 30/2100 | 167/18723 | 6.16e-03 | 3.70e-02 | 30 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0472318 | Cervix | CC | Retrograde endocannabinoid signaling | 42/1267 | 148/8465 | 1.79e-05 | 1.42e-04 | 8.40e-05 | 42 |
hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa0491212 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
hsa0501716 | Cervix | CC | Spinocerebellar ataxia | 35/1267 | 143/8465 | 1.77e-03 | 7.21e-03 | 4.26e-03 | 35 |
hsa0492812 | Cervix | CC | Parathyroid hormone synthesis, secretion and action | 27/1267 | 106/8465 | 3.12e-03 | 1.19e-02 | 7.03e-03 | 27 |
hsa04062 | Cervix | CC | Chemokine signaling pathway | 43/1267 | 192/8465 | 3.60e-03 | 1.34e-02 | 7.91e-03 | 43 |
hsa049336 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa0497116 | Cervix | CC | Gastric acid secretion | 20/1267 | 76/8465 | 6.93e-03 | 2.27e-02 | 1.34e-02 | 20 |
hsa049265 | Cervix | CC | Relaxin signaling pathway | 30/1267 | 129/8465 | 7.92e-03 | 2.56e-02 | 1.51e-02 | 30 |
hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLCB1 | SNV | Missense_Mutation | | c.2245N>A | p.Val749Ile | p.V749I | Q9NQ66 | protein_coding | deleterious(0.02) | possibly_damaging(0.609) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
PLCB1 | SNV | Missense_Mutation | | c.2548G>A | p.Glu850Lys | p.E850K | Q9NQ66 | protein_coding | tolerated(0.33) | benign(0.025) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PLCB1 | SNV | Missense_Mutation | | c.978N>A | p.Phe326Leu | p.F326L | Q9NQ66 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCB1 | SNV | Missense_Mutation | rs867281730 | c.1229N>T | p.Ser410Leu | p.S410L | Q9NQ66 | protein_coding | deleterious(0) | possibly_damaging(0.672) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCB1 | SNV | Missense_Mutation | | c.662N>A | p.Pro221His | p.P221H | Q9NQ66 | protein_coding | tolerated(0.06) | possibly_damaging(0.593) | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
PLCB1 | SNV | Missense_Mutation | novel | c.351G>T | p.Leu117Phe | p.L117F | Q9NQ66 | protein_coding | tolerated(0.15) | benign(0.385) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCB1 | SNV | Missense_Mutation | novel | c.352A>T | p.Asn118Tyr | p.N118Y | Q9NQ66 | protein_coding | deleterious(0) | possibly_damaging(0.852) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCB1 | SNV | Missense_Mutation | novel | c.976T>C | p.Phe326Leu | p.F326L | Q9NQ66 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLCB1 | SNV | Missense_Mutation | | c.665G>A | p.Arg222Gln | p.R222Q | Q9NQ66 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
PLCB1 | SNV | Missense_Mutation | rs867281730 | c.1229N>T | p.Ser410Leu | p.S410L | Q9NQ66 | protein_coding | deleterious(0) | possibly_damaging(0.672) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |